Multicenter observational retrospective cohort study aiming at comparing the incidence ofventilator-associated lower respiratory tract infections between COVID-19 patients fromthe first and the second wave of the pandemic.
CoVAPid2 is a multicenter retrospective observational cohort study aiming at comparing
the incidence of ventilator-associated lower respiratory tract infections between
COVID-19 patients from the first and the second wave of the pandemic. Patients with
confirmed SARS-CoV-2 community-acquired pneumonia and receiving invasive mechanical
ventilation for more than 48h in the participating ICUs from the start of COVID pandemic
are eligible for this study. Consecutive patients will be included from the beginning of
the first wave (starting on 01-01-2020, data already collected in the CoVAPid1 study) and
the second wave (starting on 10-01-2020). 10-20 patients per wave will be included in
each center. VAT and VAP are defined using clinical, radiological and quantitative
microbiological criteria.
Inclusion Criteria:
- Major (18 years and older)
- Admitted to the ICU
- Intubated and mechanically ventilated for more than 48 hours
- With a confirmed community-acquired SARS-CoV2 pneumonia
Exclusion Criteria:
- Refusal to participate
- Lack of social security coverage
Hop Salengro - Hopital B Chr Lille
Lille, France
Saad NSEIR, MD,PhD
0320445962 - +33
Saadalla.NSEIR@CHRU-LILLE.FR
Anahita ROUZE, MD
anahita.rouze@chru-lille.fr
Saad NSEIR, MD,PhD, Principal Investigator
University Hospital, Lille